Switzerland Innovation & Finance — 2026-04-24
Switzerland's Crypto Valley continues to cement its dominance in European blockchain funding, while the country's M&A framework draws fresh attention from international legal observers. Fresh data confirms the alpine nation captured 47% of all European blockchain venture capital in 2025, raising $728 million across 31 deals — a 37% year-on-year increase. Meanwhile, new regulatory frameworks for crypto licensing and a high-profile M&A guide underscore Switzerland's maturing position as a global innovation hub.
Switzerland Innovation & Finance — 2026-04-24
Key Highlights
Crypto Valley's 2025 Funding Record — Fresh Coverage
Switzerland's Crypto Valley raised $728 million across 31 deals in 2025, capturing 47% of all European blockchain venture capital and 5% of the global total, according to the annual Crypto Valley report. Funding rose 37% year-on-year, driven significantly by a large deal involving TON (Toncoin) infrastructure.

Mathias Ruch, founder and CEO of Crypto Valley, described the area as a "maturing ecosystem" now focused not just on infrastructure but on finance and frontier technology convergence. The Valley currently hosts 1,766 active blockchain companies — up 134% since 2020.
However, the picture is not entirely rosy: the combined valuation of the top 50 Swiss-based blockchain firms stands at $467 billion, and the number of unicorns has declined from 17 to 10.
Switzerland's M&A Legal Framework — 2026 Guide Published
Legal benchmarking publication IFLR released its M&A Guide 2026 for Switzerland, authored by Christoph Neeracher, Philippe Seiler, and Raphael Annasohn of Bär & Karrer. The guide highlights Switzerland's stable legal environment for mergers and acquisitions, an area of increasing international interest as cross-border deals involving Swiss entities continue to grow.

U.S. Regulatory Fintech Developments — Cross-Border Relevance
A newsletter from Lowenstein Sandler covering the week of April 21, 2026 flagged ongoing U.S. appeals court arguments (April 16) in consolidated cases involving KalshiEX LLC and North American Derivatives Exchange regarding event contract regulation. While U.S.-based, these developments are watched closely by Swiss fintech firms with U.S. market exposure.
Analysis
Switzerland's Crypto Ecosystem: Maturing but Consolidating
The latest Crypto Valley data tells a nuanced story. The 37% funding increase and record $728 million haul confirm Switzerland's structural advantages — favorable regulation, a skilled talent base, and the Zug-Zurich corridor's reputation as a neutral, crypto-friendly jurisdiction. Zug alone accounts for 41% of companies in the ecosystem.
Yet the unicorn contraction — from 17 to just 10 — reflects a broader global trend of tighter valuations and institutional consolidation post-2022 crypto winter. Crypto Valley appears to be pivoting from a sheer headcount story to a quality-over-quantity narrative, with the top 50 firms anchoring a combined valuation of $467 billion.
The SRO (Self-Regulatory Organisation) registration landscape is also evolving. The Swiss Federal Council proposed two new FINMA license categories for crypto companies in October 2025. VQF SRO membership — a popular compliance route — takes 8–12 weeks and costs CHF 4,000–6,000 in the first year, making Switzerland an accessible but credible gateway for crypto firms seeking European legitimacy. Crypto Valley now hosts 1,749 blockchain companies under this framework.
What to Watch
-
Crypto Valley Conference 2026: Scheduled for May 28–29, 2026 in Rotkreuz, this seventh-edition conference will focus on "setting the foundation" — the current state and future development of blockchain technology. It is a key gathering for Crypto Valley stakeholders and international investors.
-
FINMA Crypto Licensing Framework: Watch for further developments on the two new FINMA license categories proposed in October 2025. Clarity on these categories could influence which international crypto firms choose Switzerland as a base in 2026.
-
Pharma sector fundamentals: While no pharma news broke in the past 7 days that meets our freshness threshold, Roche's underlying strength — with 7% sales growth to CHF 61.5 billion in its most recent annual report and ten molecules entering late-stage clinical trials — remains a key pillar of Swiss economic identity. (Note: This article is dated February 2026 and falls outside the strict 7-day window; included for context only.)
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.